757 related articles for article (PubMed ID: 31201556)
1. Targeting FXR in Cholestasis.
Keitel V; Dröge C; Häussinger D
Handb Exp Pharmacol; 2019; 256():299-324. PubMed ID: 31201556
[TBL] [Abstract][Full Text] [Related]
2. Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations.
Cariello M; Piccinin E; Garcia-Irigoyen O; Sabbà C; Moschetta A
Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1308-1318. PubMed ID: 28965883
[TBL] [Abstract][Full Text] [Related]
3. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
4. Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype.
Abu-Hayyeh S; Papacleovoulou G; Lövgren-Sandblom A; Tahir M; Oduwole O; Jamaludin NA; Ravat S; Nikolova V; Chambers J; Selden C; Rees M; Marschall HU; Parker MG; Williamson C
Hepatology; 2013 Feb; 57(2):716-26. PubMed ID: 22961653
[TBL] [Abstract][Full Text] [Related]
5. Xenobiotic Nuclear Receptor Signaling Determines Molecular Pathogenesis of Progressive Familial Intrahepatic Cholestasis.
Kim KH; Choi JM; Li F; Arizpe A; Wooton-Kee CR; Anakk S; Jung SY; Finegold MJ; Moore DD
Endocrinology; 2018 Jun; 159(6):2435-2446. PubMed ID: 29718219
[TBL] [Abstract][Full Text] [Related]
6. Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis.
Milkiewicz M; Klak M; Kempinska-Podhorodecka A; Wiechowska-Kozlowska A; Urasinska E; Blatkiewicz M; Wunsch E; Elias E; Milkiewicz P
Sci Rep; 2016 Dec; 6():39573. PubMed ID: 28008998
[TBL] [Abstract][Full Text] [Related]
7. Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling.
Meadows V; Kennedy L; Ekser B; Kyritsi K; Kundu D; Zhou T; Chen L; Pham L; Wu N; Demieville J; Hargrove L; Glaser S; Alpini G; Francis H
Hepatology; 2021 Nov; 74(5):2684-2698. PubMed ID: 34164827
[TBL] [Abstract][Full Text] [Related]
8. Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Gao X; Fu T; Wang C; Ning C; Liu K; Liu Z; Sun H; Ma X; Huo X; Yang X; Zou M; Meng Q
Toxicol Appl Pharmacol; 2018 Jun; 348():105-116. PubMed ID: 29660435
[TBL] [Abstract][Full Text] [Related]
9. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
10. Yinchen decoction protects against cholic acid diet-induced cholestatic liver injury in mice through liver and ileal FXR signaling.
Song G; Zou B; Zhao J; Weng F; Li Y; Xu X; Zhang S; Yan D; Jin J; Sun X; Liu C; Qiu F
J Ethnopharmacol; 2023 Sep; 313():116560. PubMed ID: 37149065
[TBL] [Abstract][Full Text] [Related]
11. Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.
Modica S; Petruzzelli M; Bellafante E; Murzilli S; Salvatore L; Celli N; Di Tullio G; Palasciano G; Moustafa T; Halilbasic E; Trauner M; Moschetta A
Gastroenterology; 2012 Feb; 142(2):355-65.e1-4. PubMed ID: 22057115
[TBL] [Abstract][Full Text] [Related]
12. Postprandial FGF19-induced phosphorylation by Src is critical for FXR function in bile acid homeostasis.
Byun S; Kim DH; Ryerson D; Kim YC; Sun H; Kong B; Yau P; Guo G; Xu HE; Kemper B; Kemper JK
Nat Commun; 2018 Jul; 9(1):2590. PubMed ID: 29968724
[TBL] [Abstract][Full Text] [Related]
13. Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders.
Molinaro A; Marschall HU
Biochem Soc Trans; 2022 Feb; 50(1):361-373. PubMed ID: 35191955
[TBL] [Abstract][Full Text] [Related]
14. Defective FXR-FGF15 signaling and bile acid homeostasis in cystic fibrosis mice can be restored by the laxative polyethylene glycol.
Bertolini A; van de Peppel IP; Doktorova-Demmin M; Bodewes FAJA; de Jonge H; Bijvelds M; Verkade HJ; Jonker JW
Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G404-G411. PubMed ID: 30653340
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice.
Kim YC; Jung H; Seok S; Zhang Y; Ma J; Li T; Kemper B; Kemper JK
Hepatology; 2020 Jun; 71(6):2118-2134. PubMed ID: 31549733
[TBL] [Abstract][Full Text] [Related]
16. Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15.
Zhou M; Luo J; Chen M; Yang H; Learned RM; DePaoli AM; Tian H; Ling L
J Hepatol; 2017 Jun; 66(6):1182-1192. PubMed ID: 28189755
[TBL] [Abstract][Full Text] [Related]
17. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Bordoni M; Roselli R; Di Giorgio C; Baldoni M; Ricci P; Monti MC; Morretta E; Zampella A; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158733. PubMed ID: 32371093
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in the Digestive, Metabolic and Therapeutic Effects of Farnesoid X Receptor and Fibroblast Growth Factor 19: From Cholesterol to Bile Acid Signaling.
Di Ciaula A; Bonfrate L; Baj J; Khalil M; Garruti G; Stellaard F; Wang HH; Wang DQ; Portincasa P
Nutrients; 2022 Nov; 14(23):. PubMed ID: 36500979
[TBL] [Abstract][Full Text] [Related]
19. Role of farnesoid X receptor in cholestasis.
Yuan ZQ; Li KW
J Dig Dis; 2016 Aug; 17(8):501-509. PubMed ID: 27383832
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis.
Byun S; Jung H; Chen J; Kim YC; Kim DH; Kong B; Guo G; Kemper B; Kemper JK
J Biol Chem; 2019 May; 294(22):8732-8744. PubMed ID: 30996006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
